DAVENPORT & Co LLC Decreases Position in Genmab A/S (NASDAQ:GMAB)

DAVENPORT & Co LLC decreased its position in Genmab A/S (NASDAQ:GMAB) by 21.4% during the fourth quarter, Holdings Channel.com reports. The fund owned 26,150 shares of the company’s stock after selling 7,112 shares during the quarter. DAVENPORT & Co LLC’s holdings in Genmab A/S were worth $546,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its position in shares of Genmab A/S by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock valued at $186,000 after acquiring an additional 827 shares during the period. R Squared Ltd purchased a new position in shares of Genmab A/S in the fourth quarter valued at about $93,000. Blue Trust Inc. increased its position in shares of Genmab A/S by 33.4% in the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company’s stock valued at $120,000 after acquiring an additional 1,442 shares during the period. SG Americas Securities LLC increased its position in shares of Genmab A/S by 82.7% in the fourth quarter. SG Americas Securities LLC now owns 26,396 shares of the company’s stock valued at $551,000 after acquiring an additional 11,949 shares during the period. Finally, Crossmark Global Holdings Inc. increased its position in shares of Genmab A/S by 8.8% in the fourth quarter. Crossmark Global Holdings Inc. now owns 41,622 shares of the company’s stock valued at $868,000 after acquiring an additional 3,377 shares during the period. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Price Performance

Shares of NASDAQ GMAB opened at $19.00 on Friday. Genmab A/S has a 1 year low of $18.92 and a 1 year high of $31.88. The company’s 50-day moving average is $20.89 and its 200 day moving average is $23.49. The stock has a market capitalization of $12.57 billion, a P/E ratio of 18.45, a P/E/G ratio of 0.55 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The business had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. During the same period in the previous year, the firm earned $0.47 EPS. Research analysts anticipate that Genmab A/S will post 1.25 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on GMAB shares. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, Genmab A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.